AESGP, EFPIA and Medicines for Europe publish joint recommendations for better patient information leaflets
Read more
Rare Disease Moonshot: breaking down barriers to accelerate research
The Rare Disease (RD) Moonshot was set up to boost public private collaborations in the areas where there are no treatment options and there is no R&D going on.
The RD Moonshot partners put together three sets of recommendations to highlight where public-private collaborations can add most value.
Click here to learn more on the recommendations to optimise clinical trials for rare disease.
Is Europe on track to be a world leader in rare diseases?
36 million Europeans live with a rare disease. The EU needs to scale up and improve the patient journey and diagnosis, which is different from a member state to another.
Watch the full recording of the POLITICO webinar here.
The European Commission has proposed that the revised General Pharmaceutical Legislation will replace the current...
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.